- Goal Is Development of a Fully Integrated Nanochannel Chip and Reader for Single-Molecule Mapping, Enabling Direct Visualization and Analysis of Long
Strands of DNA in Context and at Very High Resolution -
PHILADELPHIA, Aug. 6 /PRNewswire/ -- BioNanomatrix, Inc., a developer of breakthrough nanoscale whole genome imaging platforms for genetic diagnostics, personalized medicine and biomedical research, today announced receipt of a grant from the National Human Genome Research Institute of the U.S. National Institutes of Health (NIH). Under the direction of BioNanomatrix principal investigator Dr. Ming Xiao, the two-year $399,020 project will develop a nanoscale platform for single-molecule haplotyping imaging and analysis of long strands of DNA at ultra-high resolution in a massively parallel format.
"We are pleased that the NIH has again recognized the potential of our revolutionary nanoscale single-molecule imaging and analysis technology by awarding us this new grant, which is explicitly intended to support the development of a platform to produce consistent linearization and imaging of individual DNA molecules, allowing for high resolution mapping of labeled genomic sites," said Han Cao, Ph.D., chief scientific officer of BioNanomatrix. "This added support will help us accelerate the development of the platform, which we believe could add significantly to the understanding of genetic diseases by increasing access to whole genome analysis and by allowing researchers to view and analyze the critical haplotype information that is currently difficult to obtain."
The goal of the project is to develop a fully integrated nanochannel
chip and reader capable of single-molecule mapping of linearized genomic
material extracted directly from a sample, enabling direct visualization
and analysis of long strands of DNA in context and at very high resolution.
The platform is designed to accommodate massively parallel analyses of
|SOURCE BioNanomatrix, Inc.|
Copyright©2008 PR Newswire.
All rights reserved